Trials / Completed
CompletedNCT00196755
Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevelamer Hydrochloride (Renagel®) | Sevelamer hydrochloride three times per day with each meal |
| DRUG | Calcium acetate (PhosLo® ) | Calcium acetate three times per day with each meal |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2006-03-01
- Completion
- 2006-04-01
- First posted
- 2005-09-20
- Last updated
- 2015-03-18
Locations
17 sites across 7 countries: Belgium, Denmark, France, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00196755. Inclusion in this directory is not an endorsement.